XBiotech
XBIT
65 hedge funds and large institutions have $74M invested in XBiotech in 2021 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 22 increasing their positions, 19 reducing their positions, and 10 closing their positions.
19% more capital invested
Capital invested by funds: $62.4M → $74M (+$11.6M)
16% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 19
1.02% more ownership
Funds ownership: 13.66% → 14.68% (+1%)
0% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 10
2% less funds holding
Funds holding: 66 → 65 (-1)
81% less call options, than puts
Call options by funds: $245K | Put options by funds: $1.29M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
+$2.12M |
| 2 |
State Street
Boston,
Massachusetts
|
+$2.06M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
+$1.3M |
| 4 |
BlackRock
New York
|
+$1,000K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$613K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
CAAS Capital Management
New York
|
-$1.5M |
| 2 |
Northern Trust
Chicago,
Illinois
|
-$1.16M |
| 3 |
VI
Vestcor Inc
Fredericton,
New Brunswick, Canada
|
-$303K |
| 4 |
TNB
Thomasville National Bank
Thomasville,
Georgia
|
-$218K |
| 5 |
Morgan Stanley
New York
|
-$203K |
XBIT Hedge Fund Activity: Q1 2021 in Review
65 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in XBiotech (XBIT) for Q1 2021, worth a combined $74M — up 19% from $62.4M a quarter earlier.
Fund positioning in XBIT was balanced in Q1 2021: 10 funds opened new positions, 10 closed out, 22 added to existing stakes and 19 trimmed.
The largest buyer was Wells Fargo, adding an estimated $2.12M. The largest seller was CAAS Capital Management, cutting an estimated $1.5M.
- 65 institutional investors held XBiotech (XBIT) as of Q1 2021, down from 66 in Q4 2020.
- Funds reported $74M of XBiotech stock for Q1 2021, up 19% quarter-over-quarter.
- 10 funds opened new XBiotech positions in Q1 2021 and 10 closed out, a net change of 0 holders.
- The largest XBiotech buyer in Q1 2021 was Wells Fargo, an estimated $2.12M added.
- The largest XBiotech seller in Q1 2021 was CAAS Capital Management, an estimated $1.5M sold.
Based on aggregated 13F filings for Q1 2021.